treatment withdrawal
Phase 3Small molecule
treatment withdrawal is one of 44 small molecule programs targeting Relapsing-Remitting Multiple Sclerosis. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
107 competitors in Relapsing-Remitting Multiple Sclerosis
#DrugCompanyPhaseTrials
1Copaxone
TevaPhase 3
Betaseron
BayerPhase 3
Aubagio
SanofiPhase 3
Robitussin
PfizerPhase 3
Avonex
EMD SeronoPhase 3
Fluzone
SanofiPhase 3
Rituxan
RochePhase 3
Campath
GGenzyme, a Sanofi Company
Phase 3
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for treatment withdrawal. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details